VIEW Lilly's obesity pill lags Novo's Wegovy injection in key trial – Reuters

Written by

admin

in

  1. VIEW Lilly’s obesity pill lags Novo’s Wegovy injection in key trial  Reuters
  2. Lilly’s oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity  Eli Lilly and Company
  3. Novo Soars as Lilly’s Obesity Pill Disappointment Offers Relief  Bloomberg.com
  4. Eli Lilly’s key obesity pill falls short of rivals, but the company still beat on earnings  statnews.com
  5. OMX Copenhagen jumps 6% as Novo Nordisk rallies 12%  breakingthenews.net

Continue Reading

More posts